Prognostic Factors (Q62096508)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 December 2014

Language	Label	Description	Also known as
English	Prognostic Factors	scientific article published on 5 December 2014

Statements

scholarly article

0 references

Prognostic Factors (English)

0 references

author name string

Lena Specht

1

0 references

Dirk Hasenclever

2

0 references

publication date

5 December 2014

0 references

131-155

0 references

[PROPOSAL OF CLASSIFICATION AND THERAPY OF HODGKIN'S DISEASE]

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Cure of Hodgkin's Disease.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The Prognosis in Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Improved survival in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Second cancers in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Hodgkin's disease prognosis: a directly predictive equation.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic groups for management of localized Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Age-specific survival after Hodgkin's disease in a population-based cohort (United States).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Problems with using observational databases to compare treatments

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The Influence of Laparotomy on Management Decisions in Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

An analysis of prognostic factors in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Hodgkin's disease in young and elderly patients. Clinical and pathological studies. Minireview based on a doctoral thesis

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumor burden as the most important prognostic factor in early stage Hodgkin's disease.Relations to other prognostic factors and implications for choice of treatment

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumour burden as the main indicator of prognosis in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Thoracic irradiation in Hodgkin's disease: disease control and long-term complications

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Is it an E lesion or stage IV? An unsettled issue in Hodgkin's disease staging

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Serum albumin in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

A multivariate analysis of prognostic factors in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Systemic disturbance in Hodgkin's disease and its relation to histopathology and prognosis (BNLI report No. 30).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The clinical value of tumor burden at diagnosis in Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumor burden in Hodgkin's lymphoma: much more than the best prognostic factor

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Biomarkers and prognosis in malignant lymphomas.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Hodgkin's disease in the elderly: current status and future directions.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Hodgkin disease survival in Europe and the U.S

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curi

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Classification of Hodgkin's disease biopsies by a panel of four histopathologists. Report of 1,140 patients from the German National Trial.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Hodgkin's disease: a quantitative evaluation by computed tomography of tumor burden

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Stage III Hodgkin's disease--long-term results following chemotherapy, radiotherapy and combined modality therapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? German Hodgkin's Lymphoma Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

High-risk Hodgkin's disease prognostic factors

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic role of serum beta 2-microglobulin in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The Clinical Significance of Cytokines and Soluble Forms of Membrane-Derived Activation Antigens in the Serum of Patients with Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors for patients with Hodgkin disease in first relapse

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (AB

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Salvage radiotherapy in recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Salvage radiotherapy following chemotherapy failure in Hodgkin's disease--what is its role?

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Salvage radiotherapy for hodgkin's disease following chemotherapy failure

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Autologous transplantation in relapsed and refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Outcomes of Hodgkin’s Lymphoma Patients with Relapse or Progression following Autologous Hematopoietic Cell Transplantation

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The disappearance of prognostic factors in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

The role of radiotherapy for early stage Hodgkin's disease: limitations and perspectives

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-12505-3_8

31 March 2020

Identifiers

10.1007/978-3-319-12505-3_8

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q62096508&oldid=1452442529"